Reduced-target versus full-target IMRT after chemo and immunotherapy for metastatic nasopharyngeal cancer
A Multicenter, Phase III Non-Inferiority Clinical Trial: Locoregional Volume-Reduction Versus Conventional Definitive Target IMRT Following Full-Dose Chemotherapy for Treatment-Naïve Distant Metastatic Nasopharyngeal Carcinoma Undergoing Full-Course Immunotherapy
This trial will test whether smaller (reduced-target) radiotherapy after first-line chemo plus immunotherapy works as well as standard full-target radiotherapy for people with newly diagnosed distant metastatic nasopharyngeal cancer who responded to initial treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 166 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Zhuhai) |
| Trial ID | NCT07188584 on ClinicalTrials.gov |
What this trial studies
This phase III non-inferiority trial enrolls adults with newly diagnosed distant metastatic non-keratinizing nasopharyngeal carcinoma who achieved a complete or partial response after platinum-doublet chemotherapy combined with a PD-1 inhibitor. Participants are randomized to receive either reduced-target intensity-modulated radiotherapy (IMRT) focused on gross and high-risk areas or conventional full-target IMRT including prophylactic low-risk CTV2, following standard dose prescriptions. The primary endpoints are 2-year progression-free survival and the incidence of grade 3 or higher radiation-related adverse events, with safety and overall survival as key secondary outcomes. If non-inferiority is confirmed, the reduced-target approach could establish a new standard that preserves efficacy while substantially lowering radiotherapy toxicity.
Who should consider this trial
Good fit: Adults 18–70 with newly diagnosed distant metastatic non-keratinizing (WHO II/III) nasopharyngeal carcinoma, ECOG 0–1, who achieved CR or PR after first-line platinum-doublet chemotherapy plus a PD-1 antibody are the intended candidates.
Not a fit: Patients with ECOG >1, keratinizing histology, inadequate response to first-line chemoimmunotherapy, or inability to receive radiotherapy at participating centers are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, patients could achieve comparable cancer control with substantially less radiation-related toxicity and improved quality of life.
How similar studies have performed: Previous randomized and large observational studies have shown survival benefit from adding local radiotherapy to systemic therapy in metastatic NPC, but randomized phase III evidence specifically testing a reduced-target approach in the immunotherapy era is limited and largely unproven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18 years - 70 years. * The patient has signed the informed consent form and is willing and able to follow the visit schedule, treatment plan, laboratory tests and other research procedures as per the research plan. * Newly diagnosed distant metastasis patients who achieved complete response (CR) or partial response (PR) after receiving adequate first-line systematic therapy (platinum-containing doublet chemotherapy + PD-1 monoclonal antibody). * Nasopharyngeal carcinoma non-keratinizing carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III), confirmed by histological and/or cytological examination, with metastatic lesions detected on imaging (biopsy of metastatic tissue is preferred but not mandatory). * Clinical stage: TanyNanyM1, stage IVB (AJCC 9th edition). * ECOG score: 0-1. * Female subjects with reproductive capacity must have a negative urine or serum pregnancy test within 7 days prior to enrollment, and must agree to take effective contraceptive measures during the study. * For male subjects, if the female partner still has reproductive capacity, the male subject must agree to take effective contraceptive measures during the study. Exclusion Criteria: * Patients with malignant pleural effusion or those with other malignant tumors * Patients who have received ≥2 prior lines of systemic therapy. * Patients with known or suspected autoimmune diseases, including dementia and epileptic seizures. * Patients with grade ≥ II coronary heart disease, arrhythmia (including QTc interval prolongation in males \> 450 ms, females \> 470 ms) and heart failure. * Patients who received systemic or local glucocorticoid treatment within 4 weeks prior to enrollment. * Patients with comorbidities requiring long-term use of immunosuppressive drugs or requiring systemic or local use of corticosteroids at immunosuppressive doses. * Patients with active pulmonary tuberculosis (TB), who are undergoing anti-TB treatment or have received anti-TB treatment within 1 year prior to screening. * HIV-positive individuals; HBsAg positive and HBV DNA copy number positive (quantitative detection ≥ 1000 cps/ml); chronic hepatitis C blood screening positive (HCV antibody positive). * Patients who received any anti-infective vaccine (such as influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment. * At the time of randomization, the expected lifespan of the patients was less than 6 months. * Other patients deemed unsuitable for inclusion by the treating physicians.
Where this trial is running
Zhuhai
- The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000 Recruiting — Zhuhai, China (Recruiting)
Study contacts
- Study coordinator: Ming-Yuan Chen, MD,PhD
- Email: chmingy@mail.sysu.edu.cn
- Phone: 86-13903052650
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.